The committee recommended Keytruda's subcutaneous form for all indications and as neoadjuvant/adjuvant treatment in PD-L1-positive head and neck cancer.

Merck & Co. has won a trio of positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use. Merck on Friday said CHMP has recommended approval of the ...

European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted two positive opinions for Merck’s (MRK) blockbuster cancer drug Keytruda, the company said on Friday.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s ...

Patients at York Hospital being treated for advanced head and neck cancer will be able to access a trial for a potential ...

Patients at York Hospital being treated for advanced head and neck cancer will be able to access a trial for a potential ...

Nanobiotix S.A. stock surges on promising cancer trial results and major partnership. Click for more on NBTX stock and why ...

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

While some patients may view head and neck cancer screenings as an unnecessary optional screening, these exams can be ...

Half-Year Results and Business UpdatePositive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC) 100% ...

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck ...

Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for ...